RO4602522
2 trials in this asset. Source: ClinicalTrials.gov, as of July 21, 2026.
Trials
2
Ongoing
0
Recruiting
0
Completed
2
Sites
139
Countries
12
Endpoints
23
Composite endpoints
0
Distinct sites and countries across this asset's trials. A site running several of its trials counts once, matching the map. All 23 linked ClinicalTrials.gov endpoints are classified into the categories below. Trial and endpoint linkage does not by itself establish treatment attribution for every endpoint.
Development
Where the program stands
Trials by phase
Trials by status
Evidence coverage
What this asset has been measured on
Endpoints grouped into outcome categories, ranked by how often they are measured across this asset's trials.
Most-measured metrics
Top 20 metrics across this asset's endpoints
Normalized metric codes are available for 3 of 23 classified ClinicalTrials.gov endpoints for this asset; the ranking below covers that coded subset.
2
1
Trials
Trials for this asset
Every trial for this asset, with the same search, filters, and sort as the Trials tab.
2 of 2
| Asset / Disease area | Key I/E criterion | Evidence | ||||||
|---|---|---|---|---|---|---|---|---|
| MAyflOwer RoADA Study of RO4602522 in Participants With Moderate Severity Alzheimer Disease on Background Alzheimer Disease Therapy | Donepezil, Galantamine, Memantine, Rivastigmine, RO4602522 Alzheimer’s disease | Alzheimer's disease | Ph 2 | Completed | 142 | Jun 2015 | 1 | |
| NCT01701089A Study of RO4602522 in Patients With Alzheimer Disease and in Healthy Volunteers | RO4602522 Alzheimer’s disease | Alzheimer's disease | Ph 1 | Completed | 1 | May 2013 | - |
Showing 1-2 of 2 trials